Fluorescent Anti-CEA Antibody Detects Submillimeter Colon Cancer Metastases
Journal of Surgical Research · 2026-10 · 326 · 374-382
DOI: 10.1016/j.jss.2026.06.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Research, 2026-10. Verfasst von Javier Bravo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California San Diego, San Diego, California; VA San Diego Healthcare System, San Diego, California. Hauptthemen laut MEDLINE: Carcinoembryonic Antigen, Colonic Neoplasms, Neoplasm Micrometastasis, Optical Imaging. Die Arbeit nennt 23 Literaturangaben. Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
INTRODUCTION: SGM-101, a near-infrared 700 nm emitting fluorophore-conjugated antibody targeting carcinoembryonic antigen, has shown promise in colorectal cancer (CRC) imaging. The present study determines whether colocalization of SGM-101 fluorescence excited at 700 nm and tumor luciferase expression can detect colon cancer micrometastases in orthotopic nude mouse models using the Pearl small animal preclinical imaging system and an FDA-approved (U.S. Food and Drug Administration) Arthrex Synergy Vision and exoscope clinical imaging system. MATERIALS AND METHODS: LS174T-luciferase human CRC cells were implanted in athymic mice to establish subcutaneous (n = 4) and orthotopic (n = 8) tumor models. Mice received 60 μg of SGM-101 intravenously 72 h prior to imaging and 4.5 mg of D-luciferin via intraperitoneal injection 10 min before imaging. Imaging was performed with the Pearl Trilogy System and the Arthrex Synergy Vision System and exoscope to detect SGM-101 tumor labeling and luciferase expression, including primary tumors and micrometastases. Colocalization of SGM-101 tumor labeling was determined by calculating tumor-to-background fluorescence ratios (TBRs). Biodistribution analysis and histologic confirmation were performed postmortem. RESULTS: SGM-101 fluorescence colocalized with tumor luciferase in both subcutaneous and orthotopic tumor models. Subcutaneous tumors showed TBRs of 3.54 and 2.51. Orthotopic tumors demonstrated strong labeling with an average TBR of 5.24 (±0.93). Microscopic peritoneal wall metastases (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of California San Diego, San Diego, California; VA San Diego Healthcare System, San Diego, California.
- Department of Surgery, University of California San Diego, San Diego, California.
- Department of Surgical Oncology, City of Hope National Medical Center, Duarte, California.
- Surgimab, Montpellier, France.
- Department of Surgery, University of California San Diego, San Diego, California; VA San Diego Healthcare System, San Diego, California; AntiCancer Inc., San Diego, California.
- Department of Surgery, University of California San Diego, San Diego, California; VA San Diego Healthcare System, San Diego, California. Electronic address: mbouvet@ucsd.edu.
Förderung
- National Institutes of Health
Zitieren
APA
Bravo, J., Liu, S., Jaiswal, S., Amirfakhri, S., Eddins, B., Kobayashi, K., Zaker, J., Lwin, T. M., Cailler, F., Hoffman, R. M., & Bouvet, M. (2026). Fluorescent Anti-CEA Antibody Detects Submillimeter Colon Cancer Metastases. Journal of Surgical Research, 326, 374-382. https://doi.org/10.1016/j.jss.2026.06.025
Vancouver
Bravo J, Liu S, Jaiswal S, Amirfakhri S, Eddins B, Kobayashi K, et al. Fluorescent Anti-CEA Antibody Detects Submillimeter Colon Cancer Metastases. Journal of Surgical Research. 2026;326:374-382. doi:10.1016/j.jss.2026.06.025
BibTeX
@article{Bravo2026,
author = {Bravo, Javier and Liu, Shanglei and Jaiswal, Sunidhi and Amirfakhri, Siamak and Eddins, Blackberrie and Kobayashi, Keita and Zaker, Jasmin and Lwin, Thinzar M and Cailler, Françoise and Hoffman, Robert M and Bouvet, Michael},
title = {Fluorescent Anti-CEA Antibody Detects Submillimeter Colon Cancer Metastases},
journal = {Journal of Surgical Research},
year = {2026},
volume = {326},
pages = {374--382},
doi = {10.1016/j.jss.2026.06.025}
}
EUVIMED